This Hamburg-based patent attorney firm provides its clients with all-round support in oppositions, nullity suits and patent filing. The well-positioned team is firmly established among regular clients, most of which are notable international companies from the pharma, biotech and chemicals sectors. Litigation for Amgen made good headway. The litigation team receives much public attention for its representation of Monsanto at the EPO, even after the merger with Bayer. In infringement proceedings, highlights included litigation for Medac in the economically important pharma proceedings involving cytostatic pemetrexed. Prosecution work also made steady progress. The IP boutique frequently develops its own young talent, but shrunk slightly with the retirement of Dr. Georg Both.
Patent litigation with a technical focus on pharmaceuticals, biotech and chemicals.
Albrecht von Menges (“experienced”, competitor), Peter Franck, Ulrich-Maria Gross, Heinz-Peter Muth (“outstanding preparation”, competitor)
14 patent attorneys
Dr. Georg Both (retirement)
All-round IP practice focusing on patent prosecution with broad technical expertise. Opposition and nullity suits. Infringement proceedings with external litigators. Also trademarks and unfair competition.
Litigation: Amgen (defendant) against Regeneron/Sanofi over antibodies; Big Ben (claimant) against Nintendo over consumer electronics; Ivoclar (defendant) against Vita Zahnfabrik over lithium silicate glass ceramic; Medac (defendant) against Eli Lilly over cancer drug pemetrexed. Prosecution (all public knowledge): filing and oppositions for BMS, W. R. Grace, Chr. Hansen, Ivoclar, KRKA, Monsanto; filing for Exxon, Helmholtz-Zentrum Geesthacht Centre for Materials and Coastal Research, Poly-Med, H&T Kongsberg Automotive, Marsberg, Presspart, Sealed Air.